Leerink Partners Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $862.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target cut by Leerink Partners from $980.00 to $862.00 in a research note released on Tuesday. They currently have a market perform rating on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on REGN. Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday. Oppenheimer reduced their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:REGN opened at $722.07 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market cap of $79.35 billion, a PE ratio of 17.87, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock’s 50-day moving average is $717.27 and its 200 day moving average is $914.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Mizuho Securities USA LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Simplify Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares during the period. Golden State Equity Partners increased its stake in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $1,334,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.